Dermapharm Holding Past Earnings Performance
Past criteria checks 2/6
Dermapharm Holding has been growing earnings at an average annual rate of 1.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 11.3% per year. Dermapharm Holding's return on equity is 15.2%, and it has net margins of 7.7%.
Key information
1.8%
Earnings growth rate
1.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 11.3% |
| Return on equity | 15.2% |
| Net Margin | 7.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dermapharm Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,176 | 91 | 283 | 0 |
| 30 Jun 24 | 1,147 | 83 | 282 | 0 |
| 31 Mar 24 | 1,129 | 57 | 274 | 0 |
| 31 Dec 23 | 1,151 | 62 | 271 | 0 |
| 30 Sep 23 | 1,172 | 95 | 248 | 0 |
| 30 Jun 23 | 1,151 | 123 | 228 | 0 |
| 31 Mar 23 | 1,128 | 146 | 212 | 0 |
| 31 Dec 22 | 1,041 | 134 | 191 | 0 |
| 30 Sep 22 | 1,024 | 176 | 185 | 0 |
| 30 Jun 22 | 1,004 | 185 | 180 | 0 |
| 31 Mar 22 | 980 | 211 | 173 | 0 |
| 31 Dec 21 | 960 | 210 | 169 | 0 |
| 30 Sep 21 | 902 | 162 | 168 | 0 |
| 30 Jun 21 | 858 | 123 | 167 | 0 |
| 31 Mar 21 | 828 | 95 | 168 | 0 |
| 31 Dec 20 | 808 | 86 | 158 | 0 |
| 30 Sep 20 | 775 | 80 | 142 | 0 |
| 30 Jun 20 | 760 | 77 | 134 | 0 |
| 31 Mar 20 | 743 | 85 | 119 | 0 |
| 31 Dec 19 | 714 | 77 | 116 | 0 |
| 30 Sep 19 | 674 | 73 | 114 | 0 |
| 30 Jun 19 | 639 | 77 | 105 | 0 |
| 31 Mar 19 | 611 | 73 | 100 | 0 |
| 31 Dec 18 | 584 | 75 | 92 | 0 |
| 30 Sep 18 | 558 | 75 | 96 | 0 |
| 30 Jun 18 | 525 | 76 | 89 | 0 |
| 31 Mar 18 | 498 | 79 | 82 | 0 |
| 31 Dec 17 | 480 | 78 | 78 | 0 |
| 30 Sep 17 | 486 | 84 | 70 | 0 |
| 31 Dec 16 | 455 | 77 | 71 | 0 |
| 31 Dec 15 | 396 | 13 | 65 | 0 |
| 31 Dec 14 | 402 | 0 | 67 | 0 |
Quality Earnings: DMP has high quality earnings.
Growing Profit Margin: DMP's current net profit margins (7.7%) are lower than last year (8.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DMP's earnings have grown by 1.8% per year over the past 5 years.
Accelerating Growth: DMP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DMP had negative earnings growth (-4.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.2%).
Return on Equity
High ROE: DMP's Return on Equity (15.2%) is considered low.